SYY Sysco Corporation posts narrow Q1 2026 EPS miss shares dip 088 on muted investor reaction Moderna Inc MRNA Counterparty Arbutus Biopharma Secures Regulatory Catalyst Amid Settled LNP Licensing Agreement Why Simulations Plus SLP business model holds up in any market Extends Gains 20260505 SUPN Supernus Pharmaceuticals delivers huge Q4 2025 EPS beat but shares dip 113 percent in todays trading